{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T13:32:16Z","timestamp":1743082336648},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To describe the real\u2010world effectiveness and safety of bosutinib in patients with chronic myeloid leukemia (CML).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a multi\u2010center, retrospective, non\u2010interventional chart review study conducted in 10 hospitals in the United Kingdom and the Netherlands.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty\u2010seven patients were included. Bosutinib was the third\u2010line tyrosine kinase inhibitor (TKI) in 33 (38%) and fourth\u2010line in 44 (51%) patients. Median treatment duration was 15.6\u00a0months. Among 84 patients in chronic phase (CP) at baseline, 26 (31%) switched to bosutinib due to resistance and 57 (68%) due to intolerance to prior TKIs. Cumulative complete cytogenetic and major molecular response rates in CP patients were 67% and 55%, respectively. After a median follow\u2010up of 21.5\u00a0months, nine (11%) patients in CP died; estimated overall survival rates at 1 and 2\u2009years postbosutinib initiation were 95% and 91%, respectively. Overall, 33\/87 (38%) patients discontinued bosutinib due to either lack of efficacy\/disease progression (17%), adverse events (14%), death (2%), or other reasons (5%). Eighty\u2010two (94%) patients experienced \u22651 adverse event possibly related to bosutinib, most commonly diarrhea (52%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Bosutinib used in routine clinical practice in heavily pretreated patients with CML is an effective treatment for patients in CP and is generally tolerable.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13775","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T10:52:17Z","timestamp":1649674337000},"page":"90-99","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A retrospective observational research study to describe the real\u2010world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands"],"prefix":"10.1111","volume":"109","author":[{"given":"Simone","family":"Claudiani","sequence":"first","affiliation":[{"name":"Imperial College Healthcare NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J. W. M.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, location VUmc, Hematology Cancer Center Amsterdam  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Byrne","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust  Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Smith","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust  Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Blijlevens","sequence":"additional","affiliation":[{"name":"Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Raghavan","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Cancer Medicine University of Liverpool  Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Mclain\u2010Smith","sequence":"additional","affiliation":[{"name":"OPEN Health  Marlow UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela M.","family":"Carter","sequence":"additional","affiliation":[{"name":"OPEN Health  Marlow UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[{"name":"Imperial College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2314-2"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62120-0"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2325-z"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2322-2"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.09.011"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2011.11.002"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104"},{"key":"e_1_2_8_13_1","volume-title":"BOSULIF\u00ae (Bosutinib) European Public Assessment Report","author":"European Medicines Agency","year":"2013"},{"key":"e_1_2_8_14_1","volume-title":"BOSULIF\u00ae (Bosutinib) Summary of Product Characteristics","author":"European Medicines Agency","year":"2019"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23973"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24536"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3507-2"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23728"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0294"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13775","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13775","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T10:47:57Z","timestamp":1692269277000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/ejh.13775"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13775","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"2022-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}